The utility of electronic frailty index in cancer patients undergoing chemotherapy.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
799 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
(OR 2.04 -95% CI 1.58-2.64, mild frailty 1.07-95% CI 0.78-1.45); and 6 times higher in breast cancer (OR 5.73-95% CI 2.66-12.32, mild frailty OR 1.45 95% CI 0.78-2.71). [CONCLUSION] The SCARF index predicts poor outcomes from SACT, particularly in breast and colon cancer, and it requires further evaluation.
OpenAlex 토픽 ·
Frailty in Older Adults
Nutrition and Health in Aging
Cancer survivorship and care
[BACKGROUND] Frail patients with cancer (Ca) have worse survival.
- 95% CI 1.58-2.64
APA
Agnieszka Michael, Jennie Huynh, et al. (2026). The utility of electronic frailty index in cancer patients undergoing chemotherapy.. British journal of cancer. https://doi.org/10.1038/s41416-026-03389-y
MLA
Agnieszka Michael, et al.. "The utility of electronic frailty index in cancer patients undergoing chemotherapy.." British journal of cancer, 2026.
PMID
41963596 ↗
Abstract 한글 요약
[BACKGROUND] Frail patients with cancer (Ca) have worse survival. Current methods of assessment of fitness (performance status) for cancer treatment, such as chemotherapy, are time -consuming and often not used by practicing oncologists. The electronic frailty index (SCARF) is derived from a cumulative deficit frailty model and provides a measure of frailty alongside pre-existing conditions. We used this methodology to investigate whether it can predict outcomes of chemotherapy in patients with Ca.
[METHODS] The study conducted data analysis of Ca patients treated with chemotherapy in England, years 2015-2018; stage II-III breast Ca, stage III colon Ca and stage IIIB-IV non-small-cell lung Ca. The data was linked with hospital admissions to calculate 30-day chemotherapy mortality, overall survival and SCARF.
[RESULTS] The SCARF was calculated for 78,799 patients. The risk of dying within 30 days of chemotherapy in severely frail patients with colorectal cancer ≥70 y.o. was twice that of the <70 y.o. (OR 2.04 -95% CI 1.58-2.64, mild frailty 1.07-95% CI 0.78-1.45); and 6 times higher in breast cancer (OR 5.73-95% CI 2.66-12.32, mild frailty OR 1.45 95% CI 0.78-2.71).
[CONCLUSION] The SCARF index predicts poor outcomes from SACT, particularly in breast and colon cancer, and it requires further evaluation.
[METHODS] The study conducted data analysis of Ca patients treated with chemotherapy in England, years 2015-2018; stage II-III breast Ca, stage III colon Ca and stage IIIB-IV non-small-cell lung Ca. The data was linked with hospital admissions to calculate 30-day chemotherapy mortality, overall survival and SCARF.
[RESULTS] The SCARF was calculated for 78,799 patients. The risk of dying within 30 days of chemotherapy in severely frail patients with colorectal cancer ≥70 y.o. was twice that of the <70 y.o. (OR 2.04 -95% CI 1.58-2.64, mild frailty 1.07-95% CI 0.78-1.45); and 6 times higher in breast cancer (OR 5.73-95% CI 2.66-12.32, mild frailty OR 1.45 95% CI 0.78-2.71).
[CONCLUSION] The SCARF index predicts poor outcomes from SACT, particularly in breast and colon cancer, and it requires further evaluation.